Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.775
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.05 (6.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.775
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

Mon, 18th Dec 2023 16:55

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

The FTSE 100 index closed up 38.12 points, 0.5%, at 7,614.48. The FTSE 250 ended up 11.58 points, 0.1%, at 19,220.55, and the AIM All-Share closed up 1.88 points, or 0.3%, at 741.19.

The Cboe UK 100 ended up 0.5% at 760.32, the Cboe UK 250 closed up 0.1% at 16,679.25, and the Cboe Small Companies ended up 0.5% at 14,370.59.

In European equities on Monday, the CAC 40 in Paris ended down 0.4%, while the DAX 40 in Frankfurt ended down 0.6%.

On Monday, markets were digesting some hawkish comments from US Federal Reserve officials.

This is a move away from Wednesday's pivot, when the Fed left US interest rates unchanged, but signalled for cuts in 2024.

New York Federal Reserve President John Williams told CNBC's 'Squawk Box' that the central bank isn't "really talking about rate cuts right now".

Separately, Atlanta Fed President Raphael Bostic, who votes on monetary policy next year, told Reuters that he expects two rate cuts in 2024 but not starting until the third quarter. Meanwhile, Loretta Mester, the president of Cleveland Fed, said markets are a "bit ahead" of central bank on rate cuts.

AJ Bell's Russ Mould said the comments has left markets "somewhat in limbo."

Still to come this week, there are US gross domestic product readings, as well as core inflation figures. The data could give investors more guidance about where interest rates might go.

Stocks in New York were higher at the London equities close, with the DJIA up 0.2%, the S&P 500 index up 0.5%, and the Nasdaq Composite up 0.4%.

The pound was quoted at USD1.2640 at the London equities close Monday, lower compared to USD1.2693 at the close on Friday. The euro stood at USD1.0914 at the European equities close Monday, slightly higher against USD1.0912 at the same time on Friday.

We still aren't done with interest rates decision for 2023. The Bank of Japan announces its monetary policy on Tuesday.

According to a Bloomberg report last Monday citing "people familiar with the matter", the BoJ is likely to keep its ultra-loose monetary policy in place, despite recent market speculation that the negative rate may be scrapped.

Against the yen, the dollar was trading at JPY143.05, higher compared to JPY141.75 late Friday.

In the FTSE 100, BP rose 1.6%.

The oil firm said it had joined other companies in suspending transits through the Red Sea, after Yemen's Huthi rebels targeted Israel with missiles.

"In light of the deteriorating security situation for shipping in the Red Sea, BP has decided to temporarily pause all transits," a statement said.

"We will keep this precautionary pause under ongoing review, subject to circumstances as they evolve in the region," it added.

SPI Asset Management's Stephen Innes explained: "It appears that a cohort of traders are taking hedging precautions against the tail risk associated with the Strait of Hormuz, which is providing the bid today. The Houthis' focus on vessels with ties to Israeli ownership or those engaged in shipping cargo to Israel through the Red Sea has raised concerns."

Peer Shell rose 1.4%.

Brent oil was quoted at USD78.52 a barrel at the London equities close Monday, up from USD76.34 late Friday.

At the top of the index was Entain, up 4.1%. Jefferies raised the stock to 'buy' from 'hold'.

On the other hand, Fresnillo closed down 5.2%. Morgan Stanley cut the miner's stock to 'underweight' from 'equal-weight'. Housebuilders Berkeley Group and Barratt Developments were also stung by a broker downgrade, falling 3.4% and 2.5% respectively after UBS cut the stocks to 'neutral' from 'buy'.

In the FTSE 250 index, IP Group jumped 5.9%.

The investors launched a share buyback worth up to GBP20 million. The programme will run until the end of 2024.

"The board remains committed to making regular cash returns to shareholders from realisations," IP Group said.

On London's AIM, N4 Pharma surged 39%.

The pharmaceutical company announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Chief Executive Officer Nigel Theobald said: "This continued success shows that Nuvec has the potential to be successfully used as an oral delivery system with many potential applications such as a vaccine, a product for irritable bowel disease or to treat colonic cancer among many possible examples. Given the complexities involved in oral delivery this early success with Nuvec represents a potentially massive opportunity and point of difference for Nuvec and its use as delivery system to target multiple diseases."

Cap-XX plummeted 57%, after it responded to a court decision regarding its patent infringement case against Maxwell Technologies.

The Sydney-based company, which manufactures supercapacitors for portable electronic devices, started its patent infringement trial against Maxwell Technologies last Monday.

The complaint, filed in September 2019, alleged that Maxwell Technologies had directly and indirectly infringed on Cap-XX's patents for several capacitor products.

On Friday, the jury in the Delaware district court affirmed that Cap-XX's patents were invalid, thereby nullifying the accusations against Maxwell. As a result, Maxwell is not liable to pay any damages or license fees.

Gold was quoted at USD2,022.88 an ounce at the London equities close Monday, lower against USD2,034.62 at the close on Friday.

In Tuesday's UK corporate calendar, there is a consumer price index for the eurozone at 1000 GMT.

The economic calendar for has half year results from Hipgnosis Songs Fund. There is a trading statement from Nanoco.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.